James Noble

James Noble

Chairman of the Board of Directors

Born 1959. Chairman of the Board of Directors since 2020.

M.A. from the University of Oxford.

Other appointments:

Board member of Adaptimmune since 2008. Board member and Deputy Chairman of GW Pharmaceuticals since 2007.

Previous appointments:

Brings more than 30 years of industry experience from both the private and the public sector, which includes: being co-founder of Adaptimmune and founder and CEO of Immunocore. Has also been Chairman and CEO of Avidex, which was aquired by Medigene. James has held several positions as board member at companies including, among others, Medigene, PowderJect Pharmaceuticals and CuraGen Corporation.

Holds 9,500 shares, and bonds of a nominal value of SEK 2,500,000.1

 


Staffan Lindstrand

Staffan Lindstrand

Board member

Born 1962. Board member since 2002.

M.Sc. in Engineering.

Other appointments:

Partner of HealthCap since 1997, Board member of HealthCap AB, PulmonX Inc., Doctrin AB and The Swedish Association of Exchange-listed Companies.

Previous appointments:

Ten years in investment banking.

Holds 881 shares.1


Charlotte Hansson

Charlotte Hansson

Board member

Born 1969. Board member since 2020.

MSc. in Business Administration from Handelshögskolan at the University of Gothenburg.

Other appointments:

CFO at Systembolaget AB, since 2015.

Previous appointments:

Has been Group CFO & Executive VP at Cision AB. Charlotte has also been Group CFO at Addici AB. Before this she had an extensive career within business controlling, with many year at, for instance, Modern Times Group (MTG). 

Holds 2,500 shares.1


Henrik Kjaer Hansen

Henrik Kjaer Hansen

Board member

Born 1976. Board member since 2018.

BSc. in Business Administration and a MSc. in Applied Economic and Finance at Copenhagen Business School.

Other appointments: 

Senior Director, Principal Investments, Novo Holdings A/S. Board member of Xellia Pharmaceutical.

Previous appointments:

Prior to joining Novo Holdings A/S, Kjaer Hansen was employed as a Senior Vice President in Moelis & Co. in London, focusing on healthcare M&A transactions. Other previous employments include Deutsche Bank and ABN AMRO, all in London.

Does not hold any shares in Orexo.1


David Colpman

David Colpman

Board member

Born 1961. Board member since 2015. B.Sc. Pharmacy.

Other appointments:

Director of Colpman Consulting Ltd since 2014. Member of the Royal Pharmaceutical Society. Board member of HRA Pharma and Forendo Pharma Ltd.

Previous appointments:

Former Head of Global Business Development 2012–2014, Senior Vice President of Business Development at Shire plc 1999–2012. Various business development and commercial positions at Glaxo Wellcome, Novo Nordisk and Boots Pharmaceuticals.

Holds 4,379 shares.1

 


 Kirsten Detrick

Kirsten Detrick

Board member

Boarn 1965. Board member since April 2016.

MBA.

Other appointments:

Managing Director at Takeda Austria GmbH and Takeda Osteuropa Holding GmbH since July, 2016.

Previous appointments:

Vice President Global Marketing, Therapeutic Area Commercial Lead – GI at Takeda Pharmaceuticals, Executive Director positions within US as well as Global Marketing and Commercialization at Amgen Inc. 2004–2013, Various marketing and commercial positions at Bristol-Myers Squibb 1991–2004. Former member of the Board of Southern California Biomedical Council and member of Healthcare Businesswomen’s Association.

Holds 1,500 American Depository Receipts, listed in USD.1


Mary Pat Christie

Mary Pat Christie

Board member

Born 1963. Board member since 2019.

MBA.

Other appointments:

Board member of Hackensack Meridian Health’s Carrier Clinic and Restaurant Technologies. 

Previous appointments:

Managing Director at Angelo Gordon & Co., where she focused on business development of new fund strategies and new strategic alliances. Prior to that Mrs Christie worked at Cantor Fitzgerald as an Institutional Salesperson and was an original partner at the Seaport Group. Mary Pat was also the founder of Mendham Capital Management. Her career also includes high level roles at JP Morgan, Donaldson, Lufkin & Jenrette, and Fleet Bank.

Holds 1,150 American Depository Receipts, listed in USD.1


Fred George Wilkinson

Fred George Wilkinson

Board member

Born 1956. Board member since 2019

MBA., B.Sc. Pharmacy

Other appointments:

Fred currently serves as board member of Alter Pharma Group.

Previous appointments:

Has served as President and Chief Executive Officer of Impax Laboratories, Inc. from 2014 until December 2016. Prior to that, Fred held the position of President of the Specialty business at Watson Pharmaceuticals, Inc. (currently Allergan) from 2009 through 2014. Other previous employments include among others President of Duramed Pharmaceuticals, Inc., Chief Executive Officer of Columbia Laboratories, and multiple positions at Sandoz Pharmaceutical Corp. Fred has previously served as board member of Impax Laboratories, Inc., Columbia Laboratories, Inc., Moksha8 Pharmaceuticals, Inc. and Somerset Pharmaceuticals, Inc.

Holds 2,100 American Depository Receipts, listed in USD.1

As of June 30, 2021


Nikolaj Sørensen

Nikolaj Sørensen

President and CEO

Born 1972. President and CEO since 2013, employed since 2011.

B.Sc., and M.Sc., Copenhagen Business School, Denmark.

Other appointments:

Member of the Board, Bioservo Technologies AB and Moberg Pharma AB.

Previous appointments:

Senior management positions at Pfizer Inc. with a focus on commercialization in Europe and Chairman of the Board and Managing Director at Pfizer AB. Prior to Pfizer Nikolaj Sørensen served as a management consultant at Boston Consulting Group (BCG), leading several projects within M&A, commercial transformation, and turn-arounds.

Holds 88,865 shares and stock options/share awards entitling to 192,960 shares.1


Robert A. DeLuca

Robert A. DeLuca

President Orexo US Inc.

Born 1961. President of Orexo US Inc. since 2013

R.Ph.

Other appointments:

Member of the St. John’s College of Pharmacy Dean’s Advisory Board, American Society of Addiction Medicine, Academy of Managed Care Pharmacy and the American and New Jersey Pharmacists Associations.

Previous appointments:

Extensive experience establishing commercial operations in the US with a combined background in market access, marketing, and sales. Has held leadership positions at multinational pharmaceutical companies including Sanofi-Aventis, Schering Plough, Berlex and Pharmacia, and most recently served as Chief Commercial Officer at Archimedes Pharmaceuticals.

Holds 8,568 shares and stock options/share awards entitling to 99,854 shares.1


Dennis Urbaniak

Dennis Urbaniak

EVP Digital Therapeutics

Born 1969. EVP Digital Therapeutics since 2019.

Monmouth University, US, BS Business Administration/Marketing/English

Other appointments:

Member of HIMSS (Healthcare Information and Management Systems Society)

Previous appointments:

Chief Digital Officer, Havas Health & You, Chief Executive Officer, Havas Health Plus.  Prior to Havas, Managing Director Accenture Digital Life Sciences Analytics and Janssen Client Account Lead. Twenty years at Sanofi in various sales and marketing roles.

Previous volunteer experience as Board Member and Board Chair, Diabetes Hands Foundation; Executive Council Chairman, Center for Healthcare Innovation, and Executive Advisor to Monmouth University School of Science.

Holds 10,000 shares and stock options/share awards entitling to 98,500 shares.1


Michael Sumner

Michael Sumner

Chief Medical Officer

Born 1965. Chief Medical Officer since 2013.

MB BS, MRCP (UK), MBA.

Other appointments:

Scientific Advisory Board FirstString Research Inc.

Previous appointments:

Extensive experience within the pharmaceutical industry from Novartis Pharmaceuticals, Aventis Behring, Novo Nordisk and prior to joining Orexo held the position of Vice President Clinical and Medical Affairs at Shire.

Holds 29,120 shares and stock options/share awards entitling to 75,886 shares.1


Joseph DeFeo

Joseph DeFeo

EVP and Chief Financial Officer

EVP and Chief Financial Officer since 2018, employed since 2013.

Bachelor degree in accounting from Clarion University, US, and a MBA in finance from St. Joseph’s University, US.

Previous appointments:

Vice President, Finance & Administration at Orexo US Inc., 2013-2017. Prior to joining Orexo, Joseph DeFeo has worked in several senior finance positions among others establishing of US operations for a large Italian pharmaceutical company, Head of International Treasury and led finance for the commercial operations in the US for two major pharmaceutical companies. 

Holds 4,969 shares and stock options/share awards entitling to 98,200 shares.1


Cecilia Coupland

Cecilia Coupland

VP and Head of Operations

Born 1976. VP and Head of Operations since 2019, employed since 2006.

MSc in Chemical Engineering, Uppsala University, Sweden.

Previous appointments:

Head of Supply Chain & Planning at Orexo since 2014 and prior to that extensive experience of global pharmaceutical manufacturing and supply chain management, as well as drug development and project management, from various key positions at AstraZeneca and Orexo AB.

Holds 4,419 shares stock options/share awards entitling to 70,496 shares.1


Robert Rönn

Robert Rönn

VP and Head of R&D

Born 1976. VP and Head of R&D since 2019, employed since 2007.

MSc in Chemical Engineering and PhD in Medicinal Chemistry, Uppsala University, Sweden.

Previous appointments:

Head of Pharmaceutical Development & IP at Orexo AB since 2016 and prior to that extensive experience of drug discovery and development, as well as patent prosecution and litigation, from various key positions at Biolipox AB and Orexo AB.

Holds 2,805 shares and stock options/share awards entitling to 70,496 shares.1

As of June 30, 2021